Julien Bezin

Julien Bezin

Auto-generated profile, based on publicly available information

Julien Bezin

Univ. Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
JBJulien Bezin
Julien Bezin
MDMai Duong
Mai Duong
RLRégis Lassalle
Régis Lassalle
CDCécile Droz
Cécile Droz
APAntoine Pariente
Antoine Pariente
NMNicholas Moore
Nicholas Moore

10 November 2022 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
JBJulien Bezin
Julien Bezin
AGAmandine Gouverneur
Amandine Gouverneur
MPMarine Pénichon
Marine Pénichon
CMClément Mathieu
Clément Mathieu
RGRenaud Garrel
Renaud Garrel
JFJean-Luc Faillie
Jean-Luc Faillie
OBJECTIVE: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1–3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04–3.05). CONCLUSIONS: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1–3 years of treatment.

15 September 2015 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JBJulien Bezin
Julien Bezin
PGPierre‐Olivier Girodet
Pierre‐Olivier Girodet
SRSahondra Rambelomanana
Sahondra Rambelomanana
MTMaëlys Touya
Maëlys Touya
PFPaul Ferreira
Paul Ferreira
APAntoine Pariente
Antoine Pariente

24 June 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
PRPietro Rosellini
Pietro Rosellini
SASamuel Amintas
Samuel Amintas
CCCharline Caumont
Charline Caumont
RVRémi Veillon
Rémi Veillon
SGSigolène Galland-Girodet
Sigolène Galland-Girodet
PGPierre-Olivier Girodet
Pierre-Olivier Girodet

1 June 2019 in The American Journal of Medicine
Verified
Journal Article
Closed access
JBJulien Bezin
Julien Bezin
NMNicholas Moore
Nicholas Moore
YMYohann Mansiaux
Yohann Mansiaux
PSPhilippe Gabriel Steg
Philippe Gabriel Steg
APAntoine Pariente
Antoine Pariente

20 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JGJordan Guillot
Jordan Guillot
SMSandy Maumus-Robert
Sandy Maumus-Robert
AMAlexandre Marceron
Alexandre Marceron
PNPernelle Noize
Pernelle Noize
APAntoine Pariente
Antoine Pariente
JBJulien Bezin
Julien Bezin
We aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using data from the French National Insurance databases. The study period was from 1 January 2016 to 31 December 2016. Chronic drug use was defined as uninterrupted daily use lasting ≥6 months. Chronic polypharmacy was defined as the chronic use of ≥5 medications, and chronic hyperpolypharmacy as the chronic use of ≥10 medications. For individuals aged ≥65 (older adults), PIMs were defined according to the Beers and Laroche lists, and for individuals aged 45–64 years (middle-aged) PIMs were defined according to the PROMPT (Prescribing Optimally in Middle-aged People’s Treatments) list. Among individuals with chronic polypharmacy, 4009 (46.2%) middle-aged and 18,036 (64.8%) older adults had at least one chronic PIM. Among individuals with chronic hyperpolypharmacy, these figures were, respectively, 570 (75.0%) and 2544 (88.7%). The most frequent chronic PIM were proton pump inhibitors (43.4% of older adults with chronic polypharmacy), short-acting benzodiazepines (older adults: 13.7%; middle-aged: 16.1%), hypnotics (6.1%; 7.4%), and long-acting sulfonylureas (3.9%; 12.3%). The burden of chronic PIM appeared to be very high in our study, concerning almost half of middle-aged adults and two-thirds of older adults with chronic polypharmacy. Deprescribing interventions in polypharmacy should primarily target proton pump inhibitors and hypnotics.